newsfilter
← Latest News
Business Wire·

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval Alzamend recently completed a Phase IIA Study of AL001 in Alzheimer's patients and healthy subjects showing a benign